Amandine Mveang Nzoghe1, Marielle Leboueny1, Eliane Kuissi Kamgaing2,3, Anicet Christel Maloupazoa Siawaya1, Eliode Cyrien Bongho1, Joel Fleury Djoba Siawaya4, Ofilia Mvoundza Ndjindji1, Guy-Stephan Padzys5, Bénédicte Ndeboko1,3, Simon Ategbo6,3. 1. Service Laboratoire, Centre Hospitalier Universitaire (CHU) - Mère-Enfant), Fondation Jeanne EBORI, Libreville, Gabon. 2. Pôle enfant, Service de Néotatologie, CHU- Mère-Enfant Fondation Jeanne EBORI, Libreville, Gabon. 3. Université Des Sciences de La Santé, Libreville, Gabon. 4. Service Laboratoire, Centre Hospitalier Universitaire (CHU) - Mère-Enfant), Fondation Jeanne EBORI, Libreville, Gabon. joel.djoba@gmail.com. 5. Département de Biologie Cellulaire Et Physiologie, Faculté Des Sciences, Université Des Sciences Et Techniques de Masuku, Franceville, Gabon. 6. Pôle Enfant Service de Pédiatrie, CHU- Mère-Enfant Fondation Jeanne EBORI, Libreville, Gabon.
Abstract
OBJECTIVE: Herd immunity is achieved when in a population, immune individuals are in a sufficiently large proportion. Neutralizing antibodies specific to SARS-CoV-2 that are produced following infection or vaccination are critical for controlling the spread of COVID-19. The objective of the present work was to investigate the rate of SARS-CoV-2 natural immunization in Gabonese. RESULTS: One thousand, four hundred and ninety two people were enrolled. The overall prevalence of anti-SARS-CoV-2 antibodies was 36.2%. Moreover, 76.4% of people who developed a humoral response to SARS-CoV-2 produced both anti-SARS-CoV-2 N-protein antibodies and anti-SARS-CoV-2 S-protein antibodies, which correspond to 27.7% of the total population. In infants (0-9 month), children (1-17 years) and adults, the prevalence of anti-SARS-CoV-2 antibodies was relatively the same, between 33 and 37% (any antibody types) and between 25 and 28.6% (neutralizing antibodies). In this African context, one-third (1/3) of the screened population was exposed to SARS-CoV-2 and three-quarter (3/4) of those exposed individuals developed neutralizing antibodies against SARS-CoV-2. This data suggest that herd immunity is not yet to be achieved in Gabon.
OBJECTIVE: Herd immunity is achieved when in a population, immune individuals are in a sufficiently large proportion. Neutralizing antibodies specific to SARS-CoV-2 that are produced following infection or vaccination are critical for controlling the spread of COVID-19. The objective of the present work was to investigate the rate of SARS-CoV-2 natural immunization in Gabonese. RESULTS: One thousand, four hundred and ninety two people were enrolled. The overall prevalence of anti-SARS-CoV-2 antibodies was 36.2%. Moreover, 76.4% of people who developed a humoral response to SARS-CoV-2 produced both anti-SARS-CoV-2 N-protein antibodies and anti-SARS-CoV-2S-protein antibodies, which correspond to 27.7% of the total population. In infants (0-9 month), children (1-17 years) and adults, the prevalence of anti-SARS-CoV-2 antibodies was relatively the same, between 33 and 37% (any antibody types) and between 25 and 28.6% (neutralizing antibodies). In this African context, one-third (1/3) of the screened population was exposed to SARS-CoV-2 and three-quarter (3/4) of those exposed individuals developed neutralizing antibodies against SARS-CoV-2. This data suggest that herd immunity is not yet to be achieved in Gabon.
Authors: Silvia Baroncelli; Clementina Maria Galluzzo; Stefano Orlando; Robert Mphwere; Thom Kavalo; Richard Luhanga; Roberta Amici; Marco Floridia; Mauro Andreotti; Paola Scarcella; Maria Cristina Marazzi; Marina Giuliano Journal: J Clin Virol Plus Date: 2022-09-16
Authors: Master R O Chisale; Sheena Ramazanu; Saul Eric Mwale; Pizga Kumwenda; Mep Chipeta; Atipatsa C Kaminga; Obed Nkhata; Billy Nyambalo; Elton Chavura; Balwani C Mbakaya Journal: Rev Med Virol Date: 2021-07-06 Impact factor: 11.043